Osborn Rohs Williams & Donohoe Ltd cut its position in shares of Stryker Corp. (NYSE:SYK) by 5.4% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 87,267 shares of the medical technology company’s stock after selling 4,997 shares during the period. Stryker Corp. comprises about 1.9% of Osborn Rohs Williams & Donohoe Ltd’s portfolio, making the stock its 8th largest position. Osborn Rohs Williams & Donohoe Ltd’s holdings in Stryker Corp. were worth $10,159,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Winslow Capital Management LLC purchased a new position in Stryker Corp. during the second quarter valued at $174,599,000. Capital Research Global Investors boosted its position in Stryker Corp. by 3.4% in the second quarter. Capital Research Global Investors now owns 32,980,782 shares of the medical technology company’s stock valued at $3,952,087,000 after buying an additional 1,095,549 shares in the last quarter. BlackRock Fund Advisors boosted its position in Stryker Corp. by 20.1% in the second quarter. BlackRock Fund Advisors now owns 6,280,516 shares of the medical technology company’s stock valued at $752,594,000 after buying an additional 1,051,648 shares in the last quarter. Emerald Acquisition Ltd. purchased a new position in Stryker Corp. during the second quarter valued at $104,111,000. Finally, State of Tennessee Treasury Department boosted its position in Stryker Corp. by 462.8% in the second quarter. State of Tennessee Treasury Department now owns 622,623 shares of the medical technology company’s stock valued at $74,609,000 after buying an additional 511,986 shares in the last quarter. 74.90% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Stryker Corp. (NYSE:SYK)

Shares of Stryker Corp. (NYSE:SYK) traded up 2.625% during midday trading on Tuesday, hitting $115.915. The company’s stock had a trading volume of 1,072,943 shares. Stryker Corp. has a 52-week low of $86.68 and a 52-week high of $123.55. The stock’s 50 day moving average is $113.51 and its 200-day moving average is $115.06. The firm has a market cap of $43.40 billion, a P/E ratio of 26.380 and a beta of 0.86.

Stryker Corp. (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 27th. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.02. The company had revenue of $2.83 billion for the quarter, compared to analysts’ expectations of $2.81 billion. Stryker Corp. had a net margin of 15.24% and a return on equity of 23.61%. Stryker Corp.’s revenue was up 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.25 EPS. Equities analysts predict that Stryker Corp. will post $5.78 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/29/stryker-corp-syk-is-osborn-rohs-williams-donohoe-ltds-8th-largest-position.html.

Several research analysts have recently weighed in on the company. Zacks Investment Research cut Stryker Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, September 27th. BMO Capital Markets raised Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 price objective for the company in a research report on Tuesday, November 1st. They noted that the move was a valuation call. Canaccord Genuity set a $127.00 target price on Stryker Corp. and gave the stock a “buy” rating in a report on Sunday, October 30th. Oppenheimer Holdings Inc. set a $122.00 target price on Stryker Corp. and gave the stock a “hold” rating in a report on Sunday, October 30th. Finally, SunTrust Banks Inc. started coverage on Stryker Corp. in a report on Thursday, October 13th. They set a “buy” rating and a $140.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $122.38.

In related news, VP Yin C. Becker sold 1,111 shares of Stryker Corp. stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $117.00, for a total value of $129,987.00. Following the sale, the vice president now owns 16,939 shares of the company’s stock, valued at approximately $1,981,863. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 12,000 shares of Stryker Corp. stock in a transaction that occurred on Monday, November 28th. The stock was sold at an average price of $112.73, for a total transaction of $1,352,760.00. Following the completion of the sale, the director now directly owns 193,142 shares in the company, valued at approximately $21,772,897.66. The disclosure for this sale can be found here. 7.80% of the stock is currently owned by corporate insiders.

About Stryker Corp.

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.